Supplementary Data

Supplementary Table 1. Therapeutic History of the Study Population

							p *value*[b]		
	Overall non-B	*C*	*F*	*AG*	p *value*[a]	*B*	*C vs. B*	*AG vs. B*	*F vs. B*
Number of patients	189	45	47	36		1042			
NRTI-treated patients with experience with,[c] *N* (%)	179 (94.7)	44 (97.8)	44 (93.6)	32 (88.9)		1042 (100.0)			
3TC	154 (86)	39 (88.6)	41 (93.2)	27 (84.4)		980 (94)		0.03	
FTC	40 (22.3)	13 (29.5)	10 (22.7)	6 (18.8)		156 (15.0)	0.009		
TA (AZT/d4T)	152 (98.7)	36 (81.8)	41 (93.2)	28 (87.5)		984 (94.4)	0.0006		
ABC	32 (17.9)	4 (9.1)	12 (27.3)	5 (15.6)	0.08	272 (26.1)	0.01		
Non-TA (ddI/TDF)	134 (74.9)	35 (77.8)	39 (88.6)	17 (53.1)	0.001	734 (70.4)		0.04	0.07
NNRTI-treated patients with experience with,[c] *N* (%)	81 (42.9)	20 (44.4)	23 (48.9)	10 (27.8)		335 (32.1)			
NVP	34 (41.5)	14 (70)	8 (33.3)	6 (60)	0.06	199 (59.4)			0.02
EFV	62 (75.6)	12 (60)	20 (83.3)	6 (60)		208 (62.1)			0.01
PI-treated patients with experience with,[c] *N* (%)	131 (69.3)	32 (71.1)	39 (83)	27 (75)		612 (58.7)			
ATV	35 (26.1)	10 (30.3)	9 (23.1)	5 (18.5)		126 (20.6)			
IDV	45 (34.3)	6 (18.2)	20 (51.3)	6 (22.2)	0.005	324 (52.9)	0.0002	0.002	
LPV	85 (63.4)	21 (63.6)	27 (69.2)	13 (48.1)		349 (57.0)			
NFV	49 (36.6)	13 (39.4)	15 (38.5)	10 (37)		326 (53.3)			0.07
SQV	26 (19.4)	6 (18.2)	14 (35.9)	1 (3.7)	0.007	189 (30.9)		0.002	

[a]Differences in the prevalence of patients with the same drug experience among the three non-B subtypes were assessed by the Chi square test (2×3 table). Only significant *p* values ($p < 0.05$) are reported.

[b]Differences in the prevalence of patients with the same drug experience between non-B subtypes and B subtype were assessed by the Fisher exact test. Only significant *p* values ($p < 0.05$) are reported.

[c]Only the proportions of patients with experience to each drug >5% are shown.

3TC, lamivudine; ABC, abacavir; ATV, atazanavir; AG, CRF02_AG; AZT, zidovudine; ddI, didanosine; d4T, stavudine; EFV, efavirenz; FTC, emtricitabine; IDV, indinavir; LPV, lopinavir; NFV, nelfinavir; *N*, number of patients; NNRTI, nonnucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; NVP, nevirapine; PI, protease inhibitors; SQV, saquinavir; TA, thymidine analogs; TDF, tenofovir.